Physician profile
Robert I Park
NPI 1861573024
$2,345.55
in general payments reported to CMS, 2019-2025
24 companies · $558 in 2025
The $558 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $97.87 · 2021: $357 · 2022: $358 · 2023: $383 · 2024: $346 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,272 · Entertainment: $13.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,272.37 |
| Entertainment | $13.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $253.11 | 2019-2024 | |
| Astellas Pharma US INC | $224.88 | 2024-2025 | Izervay |
| Genentech USA, INC. | $215.64 | 2019-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $203.89 | 2022-2025 | Syfovre |
| Genentech, INC. | $184.50 | 2024-2025 | Vabysmo, Susvimo |
| Eyepoint US, INC. | $154.64 | 2021-2022 | |
| Horizon Therapeutics Plc | $148.60 | 2021-2023 | Tepezza |
| Alimera Sciences, INC. | $146.63 | 2019-2024 | Iluvien, Yutiq |
| Regeneron Healthcare Solutions, INC. | $129.04 | 2019-2025 | Eylea Hd, Eylea |
| Novartis Pharmaceuticals Corporation | $123.63 | 2019-2020 | |
| Coherus Oncology, INC. | $84.31 | 2023 | |
| Sandoz INC. | $74.69 | 2024 | Cimerli |
| Allergan, INC. | $70.03 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $62.93 | 2022-2024 | Visudyne, Xipere |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $49.08 | 2020-2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $45.13 | 2023-2025 | Yutiq, Purified Cortrophin Gel |
| Biogen, INC. | $29.85 | 2024 | Byooviz |
| Tarsus Pharmaceuticals, INC. | $28.25 | 2025 | Xdemvy |
| Regeneron Pharmaceuticals, INC. | $27.20 | 2025 | Eylea Hd |
| Alcon Vision LLC | $22.14 | 2025 | Simbrinza |
| Aerie Pharmaceuticals, INC. | $20.08 | 2021 | |
| Merz Pharmaceuticals, LLC | $17.86 | 2022 | |
| Heidelberg Engineering, INC. | $15.52 | 2020 | |
| Optos, INC. | $13.92 | 2025 | Oct Ophthalmoscope, Panoramic Ophthalmoscope, Nfc-700 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Park listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.